# A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation

> **NCT03883100** · PHASE2 · UNKNOWN · sponsor: **Ascentage Pharma Group Inc.** · enrollment: 23 (actual)

## Conditions studied

- Chronic Myeloid Leukemia - Accelerated Phase

## Interventions

- **DRUG:** HQP1351

## Key facts

- **NCT ID:** NCT03883100
- **Lead sponsor:** Ascentage Pharma Group Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-08
- **Primary completion:** 2024-04
- **Final completion:** 2025-03
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2023-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03883100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03883100, "A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03883100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*